

The Iron Transport Protein NRAMP2 Is an Integral Membrane Glycoprotein That Colocalizes with Transferrin in Recycling Endosomes

By Samantha Gruenheid,* François Canonne-Hergaux,* Susan Gauthier,* David J. Hackam,† Sergio Grinstein,‡ and Philippe Gros*

From the *Department of Biochemistry and Center for Host Resistance, McGill University, Montreal, Quebec, Canada H3G 1Y6; and †Division of Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada M5G 1X8

Summary

The natural resistance associated macrophage protein (*Nramp*) gene family is composed of two members in mammals, *Nramp1* and *Nramp2*. *Nramp1* is expressed primarily in macrophages and mutations at this locus cause susceptibility to infectious diseases. *Nramp2* has a much broader range of tissue expression and mutations at *Nramp2* result in iron deficiency, indicating a role for *Nramp2* in iron metabolism. To get further insight into the function and mechanism of action of *Nramp* proteins, we have generated isoform specific anti-*Nramp1* and anti-*Nramp2* antisera. Immunoblotting experiments indicate that *Nramp2* is present in a number of cell types, including hemopoietic precursors, and is coexpressed with *Nramp1* in primary macrophages and macrophage cell lines. *Nramp2* is expressed as a 90–100-kD integral membrane protein extensively modified by glycosylation (>40% of molecular mass). Subcellular localization studies by immunofluorescence and confocal microscopy indicate distinct and nonoverlapping localization for *Nramp1* and *Nramp2*. *Nramp1* is expressed in the lysosomal compartment, whereas *Nramp2* is not detectable in the lysosomes but is expressed primarily in recycling endosomes and also, to a lower extent, at the plasma membrane, colocalizing with transferrin. These findings suggest that *Nramp2* plays a key role in the metabolism of transferrin-bound iron by transporting free Fe^{2+} across the endosomal membrane and into the cytoplasm.

Key words: iron • anemia • transport • infection • macrophage

Naturally occurring (1) or experimentally induced (2) mutations at the *Nramp1* (natural resistance associated macrophage protein 1)¹ locus in vivo impair macrophage function and cause susceptibility to infection by intracellular pathogens such as *Salmonella*, *Leishmania*, and *Mycobacterium* in mice. In humans, polymorphic variants at *Nramp1* are associated with increased susceptibility to tuberculosis and leprosy (3, 4). Studies in vitro in explanted cell populations have indicated that mutations at *Nramp1* affect the ability of the macrophage to restrict the intracellular replication of antigenically unrelated microorganisms. We cloned the *Nramp1* gene (5) and showed that its mRNA is expressed abundantly in macrophages (6) and in neutrophils (7) and is inducible in macrophages by exposure to cytokines and bacterial endotoxin (6). Predicted amino acid

sequence analysis indicates that *Nramp1* has many characteristics of an integral membrane transport protein including 12 putative transmembrane (TM) domains, several predicted N-linked glycosylation sites, and a sequence signature previously identified in a number of eukaryotic and prokaryotic transport proteins (5). In macrophages, direct biochemical studies have shown that *Nramp1* is a membrane phosphoglycoprotein of apparent mass 90–110 kD (8), which is expressed in the Lamp1-positive lysosomal compartment (9). Moreover, studies in phagosomes containing either latex beads or intact bacteria have shown that upon phagocytosis, *Nramp1* is recruited to the membrane of the phagosome, where it remains during its maturation to phagolysosome (9). These findings suggest that *Nramp1* may affect resistance to infection by modulating the intravesicular milieu of the bacterial phagosome.

We have identified a second *Nramp* gene in mammals, *Nramp2*, which encodes a protein highly similar to *Nramp1* (78% identity over the hydrophobic core) (10). As opposed to the phagocyte-specific expression of *Nramp1*, *Nramp2* mRNA expression has been detected in most tissues and

¹Abbreviations used in this paper: CHO, Chinese hamster ovary; CHON, *Nramp*-transfected CHO cells; Endo H, Endo- β -acetylglucosaminidase H; GST, glutathione S-transferase; MEL, erythroleukemia; *Nramp*, natural resistance associated macrophage protein; TM, transmembrane.

cell types analyzed (10–12). Recently, it was shown that the *Nramp2* gene is mutated (G185R) in two animal models of iron deficiency, the *mk* mouse (13) and the *Belgrade* rat (14). The *mk* mouse displays deficiency in intestinal iron uptake and microcytic anemia (15, 16). The *Belgrade* rat also shows a defect in intestinal iron absorption (17). Moreover, studies in oocytes have shown that *Nramp2* can transport a number of divalent cations such as Fe^{2+} , Zn^{2+} , and Mn^{2+} in a pH-dependent, electrogenic fashion associated with the symport of a single proton (12). In addition, transient overexpression of the wild type but not G185R *Nramp2* in HEK293T cells results in a robust stimulation of cellular ^{55}Fe uptake (15). Taken together, these results indicate that *Nramp2* is the transferrin-independent system responsible for dietary iron absorption in the intestine. However, the ubiquitous expression of *Nramp2* mRNA suggests that it may be involved in iron metabolism in other tissues as well. As opposed to *Nramp1*, where the cellular and subcellular localization of the protein have been established, the lack of isoform-specific, anti-*Nramp2* antibodies has precluded the identification of the cell type and of the subcellular compartment expressing this protein. Such information is critical to elucidate the role of the *Nramp2* protein in cellular iron metabolism. In particular, the demonstrated H^+ -driven, Fe^{2+} transport activity of *Nramp2*, as well as its expression in a wide variety of tissues, make it a likely candidate not only for transferrin-independent iron absorption in the intestine but also for the transferrin-dependent uptake of iron in peripheral tissues. It is well established that acidification of the endosomal compartment causes Fe^{3+} release from transferrin and that reductases then convert the Fe^{3+} to Fe^{2+} , but the mechanism of transport of Fe^{2+} across the endosomal membrane has not yet been elucidated.

Materials and Methods

Immunogens. For the production of isoform-specific polyclonal antisera directed against *Nramp2*, rabbits were immunized with fusion proteins containing glutathione *S*-transferase (GST) fused to a peptide segment derived from the amino terminal region of *Nramp2* (residues 1–71; for amino acid numbering see reference 10). This peptide is in a region of the protein which is not conserved in other *Nramp* family members, including *Nramp1* (18). The GST-*Nramp2* fusion protein was constructed in the plasmid vector pGEX (Pharmacia) as follows: The *Nramp2* sequence was amplified by PCR using oligonucleotides NF2 (5'-AAAGATCTATGGTGTGGATCC-3') and NR (5'-CTGAA-TTCGAACGCCAGAGT-3') (nucleotides 1–268), and the full-length *Nramp2* cDNA as template. The PCR product was digested with *Bgl*II and *Eco*RI and the fragment was subcloned into pGEX digested with *Bam*HI and *Eco*RI to create the in-frame GST fusion protein. Overexpression of the *Nramp2*-GST fusion protein was carried out in large scale cultures of *Escherichia coli* and the protein was purified from bacterial lysates using glutathione-Sepharose 4B (Pharmacia) as previously described (19). Purified proteins were analyzed by 7.5% SDS-PAGE and excised from the gel after light staining with 0.05% Coomassie blue in ddH_2O .

Production of Anti-*Nramp2* Antibodies. Polyclonal antibodies were produced in male New Zealand White rabbits as described previously (8). A system for affinity purification of the antibodies was devised using the same *Nramp2* peptide fused to a second fusion partner, dihydrofolate reductase modified by the addition of eight consecutive histidine residues (his-DHFR). The fusion protein construct was made as described above, except the PCR product was digested with *Eco*RI and the resulting overhangs repaired using the Klenow fragment of DNA polymerase I (Pharmacia) before digestion with *Bgl*II. The digested PCR product was ligated into *Bgl*II- and *Sma*I-digested pQE40 plasmid vector (Qiagen). The in-frame his-DHFR-*Nramp2* fusion protein construct was transformed into *E. coli* strain M15(pREP4) for expression (Qiagen). Purification was performed on Ni-NTA agarose according to experimental conditions suggested by the manufacturer (Qiagen). The polyclonal antiserum directed against the GST fusion protein was purified against the his-DHFR fusion protein by a preparative immunoblot procedure (20). The anti-*Nramp1* polyclonal antiserum (8) was affinity purified against the corresponding *Nramp1*-GST fusion protein by the same protocol.

Cell Culture. The mouse monocyte-macrophage cell lines RAW 264.7 and J774a, the mouse Sertoli cell line TM4, and the mouse kidney line mIMCD-3 were obtained from the American Type Culture Collection (ATCC). They were cultured in media and under conditions recommended by the ATCC. WEHI 3B (myelomonocyte), WEHI 231 (B lymphocyte), BI 141 (T lymphocyte), and 70Z/3 (pre-B cell) cells were cultured as described previously (21). Chinese hamster ovary (CHO) cells LR73 (22) were grown in α -MEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, 50 U/ml penicillin and 50 $\mu\text{g}/\text{ml}$ streptomycin. All media and media supplements were purchased from GIBCO BRL. Murine macrophages were obtained by peritoneal lavage, as previously described (8). We have previously described the production and characterization of RAW macrophages expressing a transfected wild-type *Nramp1* fused to a *c-myc* epitope (9). The *c-myc*-tagged *Nramp2* expression plasmid was constructed by excising the *myc*-tagged *Nramp2* cDNA from plasmid pBluescript (23) using *Spe*I and *Eco*RV sites from the polylinker, followed by cloning into the mammalian expression plasmid pCB6 (24). For expression in CHO cells, the same insert was cloned into the expression vector pMT2 (25). CHO cells were transfected by the calcium phosphate coprecipitation method (26). RAW cells were transfected by electroporation as described previously (9). Clones of stable transfectants were selected in geneticin (G418, 1 mg crude/ml final; GIBCO BRL) for 10–14 d, picked and expanded individually, and tested for protein expression by immunofluorescence using the anti-*c-myc* tag monoclonal antibody 9E10 (Babco).

Immunoblotting and Immunoprecipitation. Crude membrane fractions from the various cells were prepared as described previously (27). Protein concentration of the membrane fraction was determined by the Bradford assay (BioRad). Proteins were separated on SDS-polyacrylamide gels and transferred by electroblotting to nitrocellulose membranes. For experiments where the membrane was to be stripped and reprobed, a polyvinylidene fluoride membrane was used (Westran; Schleicher and Schuell) to reduce protein loss from the membrane during stripping. Equal loading and transfer of proteins was verified by staining the blots with Ponceau S (Sigma Chemical Co.). The blots were blocked in TBST (10 mM Tris/Cl, pH 8, 150 mM NaCl, 0.05% Tween 20, pH 8) plus 5% skim milk powder for 1 h at room temperature. Primary antibodies used were as follows: affinity purified rabbit anti-mouse *Nramp2* (1:100 dilution); affinity purified rabbit anti-

mouse Nramp1 (1:200); mouse monoclonal anti *c-myc*-epitope tag 9E10 (Babco; 1:100), rat anti-mouse transferrin receptor (Biosource International; 1:200), and rat anti-mouse Lamp1 (1:200). Anti-rabbit, anti-rat, and anti-mouse secondary antibodies conjugated to horseradish peroxidase were used at 1:10,000 (Amersham). Chemiluminescence was used for detection of immune complexes on the immunoblot (ECL; Amersham). For immunoprecipitation, CHO cells and Nramp1 and Nramp2 CHO transfectants were metabolically labeled with [³⁵S]methionine by incubating overnight in 100 μ Ci/ml of [³⁵S]methionine (DuPont) in methionine-free DMEM (GIBCO BRL) containing 10% heat-inactivated, dialyzed fetal bovine serum, 2 mM L-glutamine, and 2 mM Hepes. Immunoprecipitation was performed exactly as described previously (8).

Immunofluorescence. Cells were grown on glass coverslips and fixed with 4% paraformaldehyde in PBS for 30 min at 4°C. Immunofluorescence was performed as previously described (9) with the following modifications: incubation with the primary antibody was 1 h at 20°C for the anti-*c-myc* mouse monoclonal 9E10 (1:200; Babco), and the anti-Lamp1 rat monoclonal (1:200), or overnight at 4°C for the anti-Nramp2 antiserum (1:800) followed by anti-mouse, anti-rat, or anti-rabbit secondary antibodies conjugated to rhodamine (1:300) or FITC (1:200) (Jackson Immunochemicals). Immunofluorescence was analyzed with a Nikon microscope using the 100 \times oil immersion objective. Certain colocalization studies were carried out using a Zeiss laser confocal microscope with a 63 \times objective. Composites of confocal images were assembled and labeled using PhotoShop, Metamorph, and Freehand software. To label the lysosomal compartment, cells were incubated with 1 mg/ml lysine-fixable FITC-dextran (Molecular Probes) in growth medium for 4 h at 37°C in 5% CO₂. After washing, cells were incubated an additional 30 min to chase the dextran from the early endosomal to the lysosomal compartments. For identification of the early and recycling endosomal compartment, cells were incubated in serum-free medium containing 50 μ g/ml FITC-transferrin (Molecular Probes) for 30 min at 37°C in 5% CO₂. Phagosomes were formed by incubating the cells with 3 μ m latex beads (Sigma Chemical Co.) diluted 1:200 in complete culture medium for 15 min at 37°C in 5% CO₂. After treatments to identify the specific subcellular compartments, cells were fixed in 4% paraformaldehyde and processed for immunofluorescence.

Glycosidase Treatments. Endo- β -acetylglucosaminidase H (Endo H) and peptide *N*-glycosidase F (PNGase F) were obtained from New England Biolabs. Aliquots of membrane preparations from J774a and CHO cells were denatured before digestion in a buffer containing 0.5% SDS and 0.1 M β -mercaptoethanol for 2 min at 70°C. For Endo H digestion, samples were diluted twofold and incubated with 4,000 U of Endo H in 50 mM sodium citrate, pH 5.5, for 1 h at 37°C. The -Endo H controls were treated identically except an equivalent volume of ddH₂O was added in place of Endo H. For PNGase F digestion, samples were diluted twofold and incubated in 50 mM sodium phosphate, pH 7.5, 1% NP-40, with 500 U of PNGase F for 1 h at 37°C. The -PNGase F controls were treated identically except an equivalent volume of ddH₂O was added in place of PNGase F.

RNA Isolation and Hybridization Studies. Total cellular RNA was isolated using guanidinium-HCl solubilization and differential ethanol precipitation (28). 20 μ g of total cellular RNA were denatured in a formamide-formaldehyde mixture and loaded onto denaturing agarose gels containing 0.66 M formaldehyde. Blots were prehybridized in a solution containing 10% dextran sulfate, 1 M NaCl, 1% SDS, and heat-denatured salmon sperm

DNA (200 μ g/ml) at 65°C for 2–16 h. Hybridization was for 24 h at 65°C in the same buffer containing the radiolabeled probe (10⁶ cpm/ml of hybridization buffer; specific activity 10⁹ cpm/ μ g DNA). Blots were washed under conditions of increasing stringency up to 0.1 \times SSC and 0.1% SDS at 65°C and then exposed to Kodak XR film with two intensifying screens at -70°C for 18 h to 7 d at -80°C.

Phagosome Fractionation. Phagosomes were isolated from J774a cells by a modification of a method described previously (9). 10 subconfluent 150 mm dishes of each cell line were fed with a 1:200 dilution of blue-dyed latex beads (0.8 μ m; Sigma Chemical Co.) in culture medium for 1 h at 37°C in 5% CO₂. The cells were then washed in PBS and harvested in the presence of protease inhibitors (1 μ g/ml leupeptin, 1 μ g/ml aprotinin, 1 μ g/ml pepstatin, and 100 μ g/ml PMSF; all Boehringer Mannheim) and recovered by centrifugation (2,000 *g*, 5 min). The cell pellets were washed and resuspended in homogenization buffer (8.5% sucrose, 3 mM imidazole, pH 7.4) and homogenized by passage through a 22G needle until 90% of the cells were broken, as monitored by light microscopy. Nuclei and unbroken cells were pelleted and the supernatant loaded onto a sucrose step gradient as follows: the supernatant was brought up to 40% sucrose by addition of 62% sucrose and loaded on top of a 1-ml 62% sucrose cushion. Layers of 2 ml of 35, 25 and finally 10% sucrose (all sucrose solutions wt/wt in 3 mM imidazole, pH 7.4, plus protease inhibitors) were sequentially added to the top of the tube, and the gradients were centrifuged at 100,000 *g* for 1 h at 4°C (SW41; Beckman). Phagosomes were recovered from the 10–25% sucrose interface, washed with PBS containing protease inhibitors, and recovered by a final centrifugation at 40,000 *g* in an SW41 rotor at 4°C. The final pellets were resuspended in 2 \times Laemmli sample buffer. Phagosomes prepared by this protocol have been previously shown to be free of endoplasmic reticulum (endoplasmic, BiP, and calnexin) and Golgi apparatus (galactosyl transferase) contaminants (29).

Results

To generate an isoform-specific anti-Nramp2 antiserum, a protein segment derived from the amino terminus of Nramp2 was selected based on its predicted antigenicity and its sequence divergence from Nramp1 (28% identity). A GST-Nramp2 fusion protein containing the amino terminal Nramp2 segment was produced and used for immunization, and the anti-Nramp2 fraction was further isolated from the immune serum by affinity purification against a second immobilized Nramp2-DHFR fusion partner. The antiserum was tested for specificity by immunoblotting crude membrane fractions as well as by immunoprecipitation of [³⁵S]methionine-labeled cell lysates from transfected CHO cell clones expressing either *c-myc*-tagged Nramp1 or *c-myc*-tagged Nramp2 proteins (Fig. 1). The anti-*c-myc* monoclonal antibody (9E10 [30]) specifically recognized a species of apparent molecular mass 90–100 kD in the Nramp2-transfected CHO cells, and a protein of 85–95 kD in the *Nramp1*-transfected cells that were absent from extracts of untransfected CHO controls (Fig. 1, A and B, bottom). These protein species migrated as broad bands in SDS-acrylamide gels. In membrane preparations from Nramp2-transfected CHO cells (CHON2), the affinity-




Figure 1. After affinity purification, anti-Nrap1 and anti-Nrap2 antisera were tested for specificity and reactivity by immunoblotting against crude membrane fractions (A) as well as by immunoprecipitation of [³⁵S]methionine-labeled cell lysates (B) from CHO cells or from the same cells transfected with a *c-myc*-tagged (tag sequence EQKLISEEDL) Nrap1 (CHON1) or a *c-myc*-tagged Nrap2 (CHON2). Protein extracts were separated by SDS-PAGE and either transferred to membranes (A) or exposed to x-ray films after immunoprecipitation (B). Antisera directed against Nrap2 (top), Nrap1 (center) or a commercially available mouse monoclonal anti-*c-myc* antibody (9E10; bottom) were used. The size of the molecular mass markers (in kD) is indicated to the right of the gels.

purified anti-Nrap2 antiserum recognized a single protein species of apparent molecular mass 90–100 kD (Fig. 1 A, top). Immunoblotting analysis of the same set of membrane fractions with anti-Nrap1 antiserum revealed a single protein species of 85–95 kD in membranes from the Nrap1-transfected CHO cells (Fig. 1 A, middle). These immunoreactive bands were absent from untransfected CHO cells and from transfected cells expressing the other Nrap isoform. The electrophoretic mobility characteristics of the Nrap1 and Nrap2 detected by the respective polyclonal antisera were very similar to those of the species detected by the anti-*c-myc* antibody in the same cell extracts (Fig. 1 A, bottom). The reactivity and isoform specificity of the antibodies were confirmed by immunoprecipitation studies of [³⁵S]methionine metabolically labeled cell extracts from CHO cells or from Nrap1 and Nrap2 CHO transfectants (Fig. 1 B). These data indicate that the anti-Nrap1 and anti-Nrap2 antisera produced and purified according to our protocol are isoform specific.

Northern blotting and in situ hybridization studies have shown that, as opposed to *Nrap1*, which is expressed al-

most exclusively in mononuclear phagocytes, *Nrap2* mRNA is expressed in most tissues (10–12). We questioned whether the two Nrap proteins would display an overlapping or mutually exclusive expression pattern. Northern blot analysis of total cellular RNA from a panel of murine hematological cell lines revealed a readily detectable level of *Nrap2* mRNA expression in the macrophage lines RAW 264.7 and J774a as well as in Friend virus-transformed erythroleukemia (MEL) cells (Fig. 2 A, top; exposure time 1 wk). A much lower level of expression of *Nrap2* was found in other cell lines: WEHI 231 (B lymphocyte), WEHI 3B (myelomonocyte), 70/Z (pre-B lymphocyte), and BI 141 (T lymphocyte). In comparison, *Nrap1* mRNA expression was restricted to the macrophage cell lines RAW264.7 and J774a and is expressed at levels ~50-fold higher than that of *Nrap2* (Fig. 2 A, middle; exposure time 24 h). Thus, *Nrap1* and *Nrap2* mRNAs are coexpressed in macrophages.

To analyze Nrap2 protein expression in macrophages, membrane fractions were prepared from thioglycolate-induced primary mouse macrophages, from J774a and RAW 264.7 cultured macrophages. For comparison, membranes were also prepared from cell lines derived from tissues previously shown to express a high level of *Nrap2* mRNA: the Sertoli cell line TM4 and the kidney inner medullary collecting duct line mIMCD-3 (17). Membranes were also prepared from control and Nrap2-transfected CHO cells, as well as from two cell lines expressing low levels of *Nrap2* mRNA (Fig. 2 A, WEHI 231 and WEHI 3B). The membranes were analyzed by immunoblotting with the anti-Nrap2 antibody (Fig. 2, B and C). The antibody detected a major heterogeneous immunoreactive protein species of broad electrophoretic mobility with an apparent molecular mass of 80–90 kD in all cells tested, with the exception of WEHI 231 cells and untransfected CHO cells. The protein was most abundant in TM4, RAW 264.7, J774a and MEL cells. The protein was also detected in the membranes prepared from primary mouse macrophages and mIMCD-3 cells, although at a lower level. WEHI 3B membranes showed the lowest level of Nrap2 expression,




Figure 2. (A) Nrap2 mRNA expression in cultured cell lines. Northern blot analysis of total cellular RNA (20 µg) from mouse cell lines: BI 141 (T lymphocyte; lane 1), 70/Z (pre-B lymphocyte; lane 2), WEHI 231 (B lymphocyte; lane 3), WEHI 3B (myelomonocyte; lane 4), RAW 264.7 (macrophage; lane 5), J774a (mac-

rophage; lane 6), and MEL (erythroleukemia; lane 7). The RNA was electrophoresed in a denaturing agarose gel, followed by transfer to a nylon membrane and hybridization to gene-specific cDNA segments from either *Nrap2* (top), *Nrap1* (center), or glyceraldehyde phosphate dehydrogenase (*Gapdh*, bottom). Exposure time was 7 d for *Nrap2* and 1 d for *Nrap1* and *Gapdh*. (B) *Nrap2* protein expression in cultured cell lines. Crude membrane fractions were prepared from different cultured cell lines as well as from thioglycolate-induced primary mouse macrophages (Mφ) and were separated by SDS-PAGE. Immunoblotting was performed using the anti-Nrap2 antiserum. (C) Glycosylation of Nrap2 protein. Membrane fractions from J774a cells (lanes 1–4) and Nrap2-transfected CHO cells (lanes 5–7) were treated with endoglycosidases followed by electrophoresis and immunoblotting with the anti-Nrap2 antiserum. Membrane fractions were either mock treated (lanes 1, 3, and 5) or incubated with Endo H (lane 2) or PNGaseF (lanes 4, 6, and 7). A lighter exposure of lane 6 is shown in lane 7.

whereas WEHI 231 and untransfected CHO cells were negative for Nramp2 expression. In the positive membrane samples, the electrophoretic mobility and heterogeneity of the immunoreactive species varied, possibly due to different posttranslational modification of the protein in these cell types. Thus, *Nramp2* is expressed in a wide variety of tissues, including macrophages, and macrophages coexpress Nramp1 and Nramp2.

The apparent mass of endogenous Nramp2 estimated by SDS-PAGE is considerably greater than the 62.3 kD molecular mass predicted by the primary amino acid sequence of the cDNA. Together with the broadness of the immunoreactive band, this anomalous mobility suggests that Nramp2 may be posttranslationally modified by glycosylation. To test this hypothesis, membrane fractions from J774a cells and Nramp2-transfected CHO cells were treated with endoglycosidases followed by electrophoresis and immunoblotting. Nramp2 was resistant to digestion with Endo H (Fig. 2 C, lanes 1 and 2), which specifically cleaves high mannose and some hybrid N-linked oligosaccharides from glycoproteins. In contrast, PNGaseF, which hydrolyzes high mannose, hybrid, and complex oligosaccharides, converted the 82-kD Nramp2 species into smaller forms of approximate apparent molecular masses of 50–55 kD (Fig. 2 C, lane 4). PNGase treatment of membranes from the Nramp2 CHO transfectants also resulted in a shift of the apparent molecular mass of the protein from 85 to ~56 kD (Fig. 2 C, lanes 6 and 7). Therefore, Nramp2 is posttranslationally modified extensively by complex N-linked glycosylation.

To gain insight into the subcellular localization of Nramp2, we first performed immunofluorescence studies on CHO and RAW 264.7 transfected cells, using an antibody directed against the *c-myc* epitope attached to the carboxy terminus of the transfected Nramp2 protein. The high levels of transfected protein in these cell lines facilitated nonambiguous localization of Nramp2, without possible limitation associated with low levels of expression of the endogenous protein. We have previously observed that the *c-myc*-tagged Nramp2 protein is functional in both CHO and RAW macrophage backgrounds and carries out active Fe^{2+} transport in these cells (Govoni, G., and P. Gros, unpublished results). We initially tested whether Nramp2 localizes to the late endosomal/lysosomal compartment, as found earlier for Nramp1 (9). To label the lysosomal compartment, cells were cultured in the presence of FITC-conjugated dextran, followed by a chase period of 30 min to remove the dextran from the early endosomal compartments, before fixation and immunostaining with the anti-*c-myc* antibody. In Nramp1-transfected CHO cells, there was clear colocalization of the anti-*c-myc* staining (Fig. 3 A) and the dextran-loaded late endosomal/lysosomal compartment (Fig. 3 B). Nramp1-stained vesicles negative for FITC-dextran were also detected. In contrast, in Nramp2-transfected CHO cells, anti-*c-myc* staining revealed an intracellular network of finer punctate vesicles distributed throughout the cytoplasm (Fig. 3 C). This staining does not appear to colocalize with the FITC-dextran (Fig. 3 D). Similar results were obtained in parallel experi-

ments using the *c-myc*-Nramp1 and *c-myc*-Nramp2-transfected RAW cells (data not shown), indicating that Nramp2 is not expressed in the lysosomal compartment. Thus, Nramp1 and Nramp2 clearly appear to have distinct, nonoverlapping subcellular sites of expression.

Since Nramp2 is implicated in cellular iron uptake, it appears logical that Nramp2 be present at the plasma membrane and/or in recycling endosomes. To label these compartments, CHO (Fig. 4) and RAW transfected cells (Fig. 5) were cultured in the presence of FITC-conjugated transferrin before fixation and immunostaining with the anti-*c-myc* antibody. Analysis by confocal microscopy indicated that, as expected, transferrin (green) stained both the plasma membrane (ring-like staining at the edge of the cells) and the recycling endosomes (subcellular punctate staining) (Fig. 4 B). A very similar and overlapping pattern was observed for Nramp2, as revealed by the anti-*c-myc* antibody (red, Fig. 4 A). Superimposition of the two images (Fig. 4 C) clearly identifies colocalization (yellow) of the two signals. Certain cells stained with FITC-transferrin but




Figure 3. Subcellular localization of Nramp1 and Nramp2 in transfected CHO cells. Immunofluorescence was performed on CHO cells transfected with *c-myc*-tagged Nramp1 proteins (A and B), *c-myc*-tagged Nramp2 proteins (C and D), or with untransfected CHO controls (E and F). Immunofluorescence was with the anti-*c-myc* mouse monoclonal antibody 9E10 (A, C, and E) which detects the transfected Nramp1 and Nramp2 proteins. Lysosomes were labeled by preincubation of the cells with FITC-conjugated dextran (B, D, and F). Cells were then fixed and reacted with the anti-*c-myc* tag antibody 9E10 and a rhodamine-conjugated secondary antibody (A, C, and E), followed by examination by fluorescence microscopy and photography.




Figure 4. Colocalization of Nrap2 and transferrin in early endosomes was determined by double immunofluorescence and confocal microscopy in either CHO control cells (D–F) or CHO cells transfected with a *c-myc*-tagged Nrap2 protein (A–C and G–I). Cells were cultured in the presence of FITC-conjugated transferrin (A–F) or FITC-conjugated dextran (G–I) before fixation and immunostaining with the anti-*c-myc* tag antibody and a rhodamine-conjugated secondary antibody (A, D, and G). The slides were then examined by confocal microscopy, and the FITC (green; B, E, and H) and rhodamine (red; A, D, and G) images were overlaid (yellow identifies colocalization; C, F, and I). In the Nrap2-transfected CHO cells, the Nrap2 staining (A and G) showed extensive overlap with the distribution of FITC-transferrin (A + B = C) but not with lysosomal FITC-dextran (G + H = I). FITC-transferrin staining was observed in the untransfected CHO cells (E), but the cells were negative for anti-*c-myc* staining (D).

were negative for the *c-myc* staining, suggesting that although these cells are positive for the pSV2neo plasmid and are resistant to G418, they failed to express *c-myc*-tagged Nrap2. Such cells provide an internal control for the specificity of the anti-*c-myc* staining and for the overlapping staining with FITC-transferrin. Similarly, when untransfected CHO cells were identically processed and examined, the cells were not stained with the anti-*c-myc* antibody (Fig. 4 D), but displayed a normal pattern of staining with FITC-transferrin (Fig. 4 E). Finally, when the lysosomes of the Nrap2-transfected cells were stained with FITC-dextran (Fig. 4 H) and with the anti-*c-myc* antibody for Nrap2 (Fig. 4 G), no significant overlap between the two signals was detected (Fig. 4 I). A similar colocalization of Nrap2 and FITC-transferrin was noted in parallel experiments with RAW macrophages expressing *c-myc*-Nrap2 (Fig. 5). These results confirm that Nrap1 and Nrap2 have nonoverlapping, subcellular localization, and that Nrap2 colocalizes with transferrin in the early recycling endosomal compartment.

To confirm the endosomal localization of Nrap2 de-

termined in transfected CHO and RAW cells, we performed immunofluorescence in nontransfected cell lines that tested positive (MEL, TM4) or negative (WEHI 231) for Nrap2 expression by immunoblotting (Fig. 2). Immunofluorescence was performed with the anti-Nrap2 polyclonal antiserum and FITC-transferrin, and results are shown in Fig. 6. In MEL (Fig. 6, A and B) and TM4 (C and D) cells, the endogenous Nrap2 protein (B and D) showed very similar staining pattern to that generated by FITC-transferrin (A and C), similar to that seen in transfected cells (Figs. 4 and 5). Finally, in agreement with the absence of Nrap2 expression in WEHI 231 cells noted by immunoblotting (Fig. 2 B), no Nrap2 staining was observed in WEHI231 cells (Fig. 6 F), although the endosomal compartment of these cells could readily be labeled by FITC-transferrin (Fig. 6 E). Together, these results verify data obtained in transfected CHO and RAW cells.

The localization of Nrap2 to the plasma membrane and endosomal network raised the possibility that like Nrap1, Nrap2 may become associated with phagosomal membranes after phagocytosis. Phagosomes are initially




Figure 5. Colocalization of Nrpamp2 and transferrin in early endosomes was determined by double immunofluorescence and confocal microscopy in RAW macrophages transfected with a *c-myc*-tagged Nrpamp2 (A–C) and in untransfected control cells (D–F). Cells were cultured in the presence of FITC-conjugated transferrin before fixation and immunostaining with the primary anti-*c-myc* tag antibody (9E10) and a secondary rhodamine-conjugated, anti-mouse antibody. The slides were then examined by confocal microscopy, and the FITC (green; B and E) and rhodamine (red; A and D) images were overlaid to identify colocalization (C and F). The image in C shows colocalization of Nrpamp2 and FITC-transferrin in several of the cells in the field.




Figure 6. Subcellular localization of endogenous Nrpamp2 in cell lines. Cell lines previously shown by immunoblotting to be either positive (MEL, TM4) or negative (WEHI 231) for Nrpamp2 expression were cultured in the presence of FITC-transferrin before fixation and immunostaining with the anti-Nrpamp2 antiserum and a rhodamine-conjugated secondary antibody. The slides were then examined by confocal microscopy, and FITC (A, C, and E; transferrin) and rhodamine (B, D, and F; Nrpamp2) images were obtained from the samples. The same settings for the confocal microscope were used for all samples examined. The images show very similar subcellular localization of Nrpamp2 and FITC-transferrin in MEL (A and B) and TM4 (C and D) cells, whereas WEHI (E and F) cells are negative for Nrpamp2.

derived from the plasma membrane and are known to sequentially interact and acquire proteins from both early and late endosomes before their final fusion with lysosomes (29). We have shown that Nrpamp1 is acquired during the phagosomal maturation process, using the model system of latex bead-containing phagosomes (9). Latex bead-containing phagosomes are ideal for microscopic examination and can also be purified from cell homogenates by flotation on sucrose gradients. To determine whether Nrpamp2 can associate with the phagosomal membrane, J774a cells were fed latex beads for 1 h at 37°C, and the phagosomal fraction was isolated from cell homogenates by fractionation on sucrose gradient. Equal amounts of the purified phagosomal fraction and of a crude total membrane fraction were separated by SDS-PAGE, and the relative amount of endogenous Nrpamp2 in each sample was determined by immunoblotting. As shown in Fig. 7 A (left), Nrpamp2 was significantly enriched in purified phagosomes as compared to the crude membrane preparation. In these experiments, the Lamp1 protein (marker of the phagolysosome, center) and the transferrin receptor (marker of the plasma membrane, right) were used as controls. As expected, significant enrichment of Lamp1 was seen in the phagosomal fraction whereas the transferrin receptor was not enriched in phagosomes even though it is readily detectable in crude membrane fractions. These results suggest that Nrpamp2 becomes associated with the phagosome during its maturation to phagolysosome. Possible association of Nrpamp2 with latex beads phagosomes was further analyzed in J774a cells by immunofluorescence and confocal microscopy. J774a cells were fed latex beads and then fixed and processed by double immunofluorescence using anti-Nrpamp2 and anti-Lamp1 antibodies (Fig. 7 B). In J774a cells, the Nrpamp2 signal obtained with our antibody was weak, which limited the analysis. Nevertheless, in several of the sections analyzed a portion of the Nrpamp2 signal could clearly be seen




Figure 7. Nrap2 association with phagosomes. (A) Immunoblotting of latex bead-containing phagosomes isolated from J774a cells. Latex bead-containing phagosomes were purified from cell homogenates by subcellular fractionation on sucrose density gradients as described in Materials and Methods. Equal amounts of phagosomal proteins (P) and of a crude membrane protein extract prepared prior to phagocytosis (M) were separated by SDS-PAGE on a 7.5% gel. Proteins were transferred to nitrocellulose and the immunoblot was sequentially analyzed with anti-Nrap2 antiserum (left), anti-Lamp1 antibody (center), and anti-transferrin receptor antibody (right). The position of molecular mass markers (in kD) is indicated on the left side of the immunoblot. (B) Localization of the Nrap2 and Lamp1 proteins in J774a macrophages by immunofluorescence. J774a macrophages were allowed to phagocytose latex beads, then fixed and stained with the anti-Nrap2 antiserum and a rhodamine-conjugated secondary antibody (a), and the anti-Lamp1 antibody and a secondary antibody coupled to FITC (b). A phase contrast image of the cells shown in panels a and b is also included in panel c.

at the periphery of the bead, suggesting association with the phagosome. However, this signal was much weaker than that obtained using the anti-Lamp1 antibody. Thus, results from immunoblotting and immunofluorescence suggest the possibility that a portion of the endosomal Nrap2 protein becomes associated with the phagosome during phagolysosome maturation.

Discussion

A large body of biochemical data supports the proposal that Nrap2 functions as a transporter for several divalent cations, including Fe^{2+} (12–14, 23, 31). *Nrap2* is mutated in the *mk* mouse and in the *Belgrade* rat (13, 14), with both animals exhibiting a severe microcytic hypochromic anemia and a severe defect in iron absorption by intestinal cells (15, 16). However, in vitro studies have shown that iron acquisition is also decreased in the peripheral cells and tissues of these animals (17, 32–36) and that the anemia cannot be corrected by direct iron injections (37), suggesting a second block of iron entry into peripheral tissues. Thus, physiological consequences of *Nrap2* mutations in vivo strongly suggest that Nrap2 is not only involved in iron uptake at the level of the intestinal enterocyte but also participates in iron acquisition in other cell types as well. In peripheral tissues, cellular iron uptake is through the transferrin cycle (for review see reference 38). Diferric transferrin binds to the transferrin receptor and is internalized, and acidification of the internalized vesicles results in release of iron from transferrin followed by alkalization of the vesicles and recycling of the receptor to the cell surface (39). Iron escapes the acidified endosomal compartment to reach the cytoplasm, where it can be captured by mitochondria for heme biosynthesis and incorporation into heme-containing proteins, stored in the cytoplasm in the form of ferritin, and/or used directly for synthesis of nonheme-containing proteins (e.g., ribonucleotide reductase). The mechanism by which iron is extruded from the acidified endosome to enter the cytoplasm is unknown and has been a matter of considerable debate.

In the current study, we have raised isoform specific anti-Nrap2 antiserum and have used it to verify a number of structural and biochemical features of Nrap2 predicted from the primary amino acid sequence deduced from the cDNA. These analyses have shown that Nrap2 is an integral membrane protein which is extensively modified by N-linked glycosylation. As opposed to Nrap1, which is macrophage-specific, Nrap2 protein was found ubiquitously expressed in a majority of cell lines analyzed. The current study has also clearly established that Nrap2 and Nrap1 localize to distinct subcellular compartments. Whereas Nrap1 colocalizes with FITC-dextran in the lysosomal compartment, Nrap2 is not detectable in this compartment but rather shows clear colocalization with FITC-transferrin both at the plasma membrane and in recycling endosomes. The demonstration of Nrap2 expression in several peripheral tissues, the colocalization of Nrap2 and transferrin in plasma membrane and recycling endosomes, the iron transport properties of the Nrap2 protein, and the effect of Nrap2 mutations on iron metabolism in peripheral tissues are strong evidence that Nrap2 is responsible for transporting Fe^{2+} into the cytoplasm after acidification of the transferrin-positive endosome (Fig. 8). Interestingly, this acidification would simultaneously provide a gating mechanism for iron transport by Nrap2 and for release from transferrin (Fig. 8). Indeed, the pH dependence of iron transport by Nrap2 has been demonstrated in several systems, including *Xenopus* oocytes (12), transfected HEK293T cells (14), and CHO cells (Govoni, G., and P. Gros, unpublished results). Likewise, release of iron from transferrin and its subsequent release from endosomes is dependent on endosome acidification, which can be inhibited by bafilomycin (40) and concanamycin (41), specific inhibitors of the vacuolar H^+ -ATPase, but is insensitive to the Na^+ , K^+ -ATPase inhibitor ouabain (41, 42). This suggests a critical role for the vacuolar H^+ -ATPase in this process. Indeed, the association of vacuolar H^+ -ATPase with transferrin-positive endosomal vesicles has been demonstrated by immunohistochemical means in LLC-porcine kidney epithelial 1 cells (43).




Figure 8. Schematic representation of Nramp 2 (left) and Nramp1 (right) function. Nramp2 is present at the plasma membrane and recycling endosomes but is not functional at neutral pH. When diferric transferrin binds to the transferrin receptor, the complex is internalized. After recruitment of the V-ATPase, the endosome acidifies, causing dissociation of iron from transferrin as well as activation of Nramp2 function. Iron can then be cotransported along with a proton across the endosomal membrane into the cytosol. In the case of Nramp1, bac-

teria that contain and require iron are taken up in phagosomes at the plasma membrane. These phagosomes acquire both Nramp1 and the V-ATPase. Acidification of the phagosome provides the driving force for the cotransport of iron and protons out of the phagosome in order to sequester iron away from the bacteria.

The demonstration that Nramp1 and Nramp2 are coexpressed in the same cell type with distinct subcellular localizations suggests possible functional parallels between Nramp1 and Nramp2 (Fig. 8). Both the yeast Smf1 and the mammalian Nramp2 proteins can transport Mn^{2+} , with the latter also transporting Fe^{2+} and other divalent cations. Nramp2 and Smf1 share approximately 40% sequence identity within the conserved hydrophobic core (18). As the mammalian Nramp1 and Nramp2 proteins share almost 80% sequence identity within their hydrophobic cores, it is likely that Nramp1 is involved in the transport of divalent cations as well. The removal of such metabolically essential ions from the phagosomal space would provide an attractive explanation for the observed pleiotropic effect of *Nramp1* mutations in vivo on the replicative potential of internalized microbes that inhabit the phagosomal space in macrophages. Additionally, the observation that a portion of Nramp2 associates with latex bead phagosomes in J774a cells suggests that Nramp2 may also play a role in depleting the phagosomal space of divalent cations necessary for microbial survival.

Despite considerable efforts, transport studies in CHO and RAW cells transfected and overexpressing Nramp1 protein have so far failed to demonstrate an Nramp1-mediated transport of either ^{54}Mn or ^{55}Fe transport in these cells

(Govoni, G., and P. Gros, unpublished results). The distinct, nonoverlapping distribution of Nramp1 and Nramp2 reported here provides an explanation for this apparent lack of transport activity associated with Nramp1. While the two proteins may have the same transport potential, the observed targeting of Nramp2 to the plasma membrane and recycling endosome compartment would result in a net increase in cellular accumulation of extracellularly added, radiolabeled ligand under acidic pH transport assay conditions. On the other hand, the restricted expression of Nramp1 to the lysosomal compartment would not cause a similar increased cellular uptake of a ligand presented in the extracellular milieu, although it could act on such ligand if present in the phagolysosomal space. Therefore, it is tempting to speculate that both Nramp1 and Nramp2 have similar transport function but act at different, nonoverlapping, intracellular sites (Fig. 8). If Nramp1 and Nramp2 do indeed transport the same substrates, it is also tempting to speculate that vesicular acidification via the vacuolar H^+ -ATPase may provide a key common gating mechanism for the activation of both transporters, through fusion with vacuolar H^+ -ATPase-positive vesicles (Fig. 8). Possible similarities and differences in the mechanism of action and regulation of Nramp1 and Nramp2 in macrophages are currently being investigated.

The authors would like to thank Elia Abi-Jaoude and Dr. Danny Baranes (McGill University) for expert technical help and advice, Dr. W. Trimble (Hospital for Sick Children, Toronto) for advice on antibody purification, Dr. M. Desjardins for the gift of the anti-Lamp1 antibody, and Dr. A. Veillette for his gift of cell lines.

This work was supported by National Institutes of Health grant 1 R01 A1 35237-06 to P. Gros and a Medical Research Council of Canada (MRC) grant to S. Grinstein. P. Gros and S. Grinstein are International Scholars of the Howard Hughes Medical Institute and Career Scientists of the MRC.

Address correspondence to Philippe Gros, Department of Biochemistry, McGill University, 3655 Drum-

Received for publication 29 September 1998 and in revised form 11 December 1998.

References

1. Malo, D., K. Vogan, S. Vidal, J. Hu, M. Cellier, E. Schurr, A. Fuks, N. Bumstead, K. Morgan, and P. Gros. 1994. Haplotype mapping and sequence analysis of the mouse Nramp gene predict susceptibility to infection with intracellular parasites. *Genomics*. 23:51-61.
2. Vidal, S., M.L. Tremblay, G. Govoni, S. Gauthier, G. Sebastiani, D. Malo, E. Skamene, M. Olivier, S. Jothy, and P. Gros. 1995. The Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene. *J. Exp. Med.* 182:655-666.
3. Abel, L., F.O. Sanchez, J. Oberti, N.V. Thuc, L.V. Hoa, V.D. Lap, E. Skamene, P.H. Lagrange, and E. Schurr. 1998. Susceptibility to leprosy is linked to the human NRAMP1 gene. *J. Infect. Dis.* 177:133-145.
4. Bellamy, R., C. Ruwende, T. Corrah, K.P. McAdam, H.C. Whittle, and A.V. Hill. 1998. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. *N. Engl. J. Med.* 338:640-644.
5. Vidal, S.M., D. Malo, K. Vogan, E. Skamene, and P. Gros. 1993. Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. *Cell*. 73:469-485.
6. Govoni, G., S. Gauthier, F. Billia, N.N. Iscove, and P. Gros. 1997. Cell-specific and inducible Nramp1 gene expression in mouse macrophages in vitro and in vivo. *J. Leukoc. Biol.* 62:277-286.
7. Cellier, M., C. Shustik, W. Dalton, E. Rich, J. Hu, D. Malo, E. Schurr, and P. Gros. 1997. Expression of the human NRAMP1 gene in professional primary phagocytes: studies in blood cells and in HL-60 promyelocytic leukemia. *J. Leukoc. Biol.* 61:96-105.
8. Vidal, S.M., E. Pinner, P. Lepage, S. Gauthier, and P. Gros. 1996. Natural resistance to intracellular infections: Nramp1 encodes a membrane phosphoglycoprotein absent in macrophages from susceptible (Nramp1 D169) mouse strains. *J. Immunol.* 157:3559-3568.
9. Gruenheid, S., E. Pinner, M. Desjardins, and P. Gros. 1997. Natural resistance to infection with intracellular pathogens: the Nramp1 protein is recruited to the membrane of the phagosome. *J. Exp. Med.* 185:717-730.
10. Gruenheid, S., M. Cellier, S. Vidal, and P. Gros. 1995. Identification and characterization of a second mouse Nramp gene. *Genomics*. 25:514-525.
11. Moffett, P., M. Dayo, M. Reece, M.K. McCormick, and J. Pelletier. 1996. Characterization of msim, a murine homologue of the Drosophila sim transcription factor. *Genomics*. 35:144-155.
12. Gunshin, H., B. Mackenzie, U.V. Berger, Y. Gunshin, M.F. Romero, W.F. Boron, S. Nussberger, J.L. Gollan, and M.A. Hediger. 1997. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. *Nature*. 388:482-488.
13. Fleming, M.D., C.C. Trenor, III, M.A. Su, D. Foerzler, D.R. Beier, W.F. Dietrich, and N.C. Andrews. 1997. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. *Nat. Genet.* 16:383-386.
14. Fleming, M.D., M.A. Romano, M.A. Su, L.M. Garrick, M.D. Garrick, and N.C. Andrews. 1998. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. *Proc. Natl. Acad. Sci. USA.* 95:1148-1153.
15. Russell, E.S., D.J. Nash, S.E. Bernstein, E.L. Kent, E.C. McFarland, S.M. Matthews, and M.S. Norwood. 1970. Characterization and genetic studies of microcytic anemia in house mouse. *Blood*. 35:838-850.
16. Edwards, J.A., and J.E. Hoke. 1972. Defect of intestinal mucosal iron uptake in mice with hereditary microcytic anemia. *Proc. Soc. Exp. Biol. Med.* 141:81-84.
17. Farcich, E.A., and E.H. Morgan. 1992. Diminished iron acquisition by cells and tissues of Belgrade laboratory rats. *Am. J. Physiol.* 262:R220-224.
18. Cellier, M., G. Prive, A. Belouchi, T. Kwan, V. Rodrigues, W. Chia, and P. Gros. 1995. Nramp defines a family of membrane proteins. *Proc. Natl. Acad. Sci. USA.* 92:10089-10093.
19. Ausubel, F., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl. 1996. Current Protocols in Molecular Biology. Vol. 2. K. Janssen, editor. John Wiley and Sons Inc., New York. 16.7.1-16.7.5.
20. Smith, D.E., and P.A. Fisher. 1984. Identification, developmental regulation, and response to heat shock of two antigenically related forms of a major nuclear envelope protein in *Drosophila* embryos: application of an improved method for affinity purification of antibodies using polypeptides immobilized on nitrocellulose blots. *J. Cell. Biol.* 99:20-28.
21. Chow, L.M., D. Davidson, M. Fournel, P. Gosselin, S. Lemieux, M.S. Lyu, C.A. Kozak, L.A. Matis, and A. Veillette. 1994. Two distinct protein isoforms are encoded by ntk, a csk-related tyrosine protein kinase gene. *Oncogene*. 9:3437-3448.
22. Pollard, J.W., and C.P. Stanners. 1979. Characterization of cell lines showing growth control isolated from both the wild type and a leucyl-tRNA synthetase mutant of Chinese hamster ovary cells. *J. Cell. Physiol.* 98:571-585.
23. Pinner, E., S. Gruenheid, M. Raymond, and P. Gros. 1997. Functional complementation of the yeast divalent cation transporter family SMF by NRAMP2, a member of the mammalian natural resistance-associated macrophage protein family. *J. Biol. Chem.* 272:28933-28938.
24. Canfield, V.A., and R. Levenson. 1993. Transmembrane organization of the Na,K-ATPase determined by epitope addition. *Biochemistry*. 32:13782-13786 (erratum published 33:3142).
25. Kaufman, R.J., M.V. Davies, V.K. Pathak, and J.W.B. Hershey. 1989. The phosphorylation site of eucaryotic initiation factor 2 alters translational efficiency of specific mRNAs. *Mol. Cell. Biol.* 9:946-958.
26. Kast, C., V. Canfield, R. Levenson, and P. Gros. 1995. Membrane topology of P-Glycoprotein as determined by epitope insertion: transmembrane organization of the N-terminal domain of mdr3. *Biochemistry*. 34:4402-4411.
27. Devault, A., and P. Gros. 1990. Two members of the mouse

- mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. *Mol. Cell. Biol.* 10:1652–1663.
28. Chirgwin, J.M., A.E. Przybyla, R.J. MacDonald, and W.J. Rutter. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. *Biochemistry.* 18:5294–5299.
 29. Desjardins, M., L.A. Huber, R.G. Parton and G. Griffiths. 1994. Biogenesis of phagolysosomes proceeds through a sequential series of interactions with the endocytic apparatus. *J. Cell. Biol.* 124:677–688.
 30. Evan, G.I., G.K. Lewis, G. Ramsay, and J.M. Bishop. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. *Mol. Cell. Biol.* 5:3610–3616.
 31. Supek, F., L. Supekova, H. Nelson, and N. Nelson. 1996. A yeast manganese transporter related to the macrophage protein involved in conferring resistance to mycobacteria. *Proc. Natl. Acad. Sci. USA.* 93:5105–5110.
 32. Edwards, J.A., and J.E. Hoke. 1975. Red cell iron uptake in hereditary microcytic anemia. *Blood.* 46:381–388.
 33. Edwards, J.A., L.M. Garrick, and J.E. Hoke. 1978. Defective iron uptake and globin synthesis by erythroid cells in the anemia of the Belgrade laboratory rat. *Blood.* 51:347–357.
 34. Edwards, J.A., A.L. Sullivan, and J.E. Hoke. 1980. Defective delivery of iron to the developing red cell of the Belgrade laboratory rat. *Blood.* 55:645–648.
 35. Farcich, E.A., and E.H. Morgan. 1992. Uptake of transferrin-bound and nontransferrin-bound iron by reticulocytes from the Belgrade laboratory rat: comparison with Wistar rat transferrin and reticulocytes. *Am. J. Hematol.* 39:9–14.
 36. Garrick, M.D., K. Gniecko, Y. Liu, D.S. Cohan, and L.M. Garrick. 1993. Transferrin and the transferrin cycle in Belgrade rat reticulocytes. *J. Biol. Chem.* 268:14867–14874.
 37. Bannerman, R.M. 1976. Genetic defects of iron transport. *Fed. Proc.* 35. 11:2281–2285.
 38. Ponka, P., C. Beaumont, and D.R. Richardson. 1998. Function and regulation of transferrin and ferritin. *Semin. Hematol.* 35:35–54.
 39. Dautry-Varsat, A., A. Ciechanover, and H.F. Lodish. 1983. pH and the recycling of transferrin during receptor-mediated endocytosis. *Proc. Natl. Acad. Sci. USA.* 80:2258–2262.
 40. Teter, K., G. Chandry, B. Quinones, K. Pereyra, T. Machen, and H.P.H. Moore. 1998. Cellubrevin-targeted fluorescence uncovers heterogeneity in the recycling endosomes. *J. Biol. Chem.* 273:19625–19633.
 41. Hackam, D.J., O.D. Rotstein, W. Zhang, S. Gruenheid, P. Gros, and S. Grinstein. 1998. Host resistance to intracellular infection: mutation of natural resistance-associated macrophage protein 1 (Nramp1) impairs phagosomal acidification. *J. Exp. Med.* 188:351–364.
 42. Sipe, D.M., A. Jesurum, and R.F. Murphy. 1991. Absence of Na⁺,K⁺-ATPase regulation of endosomal acidification in K562 erythroleukemia cells. Analysis via inhibition of transferrin recycling by low temperatures. *J. Biol. Chem.* 266: 3469–3474.
 43. Yurko, M.A., and S. Gluck. 1987. Production and characterization of a monoclonal antibody to vacuolar H⁺-ATPase of renal epithelia. *J. Biol. Chem.* 262:15770–15779.